IASLC 2017

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

By

For the phase 3 KEYNOTE-024 study, researchers randomly assigned 305 patients with advanced NSCLC of any histological type to 35 cycles of pembrolizumab or 4 to 6 cycles of investigator's choice chemotherapy.

Lung Cancer Treatment in North America: Recent Advances and Future Promises

Lung Cancer Treatment in North America: Recent Advances and Future Promises

By

At the closing plenary session of WCLC, Paul A. Bunn, Jr, MD, presented a treatment algorithm for lung cancer and discussed where lung cancer research in North America is heading.

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

By

A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

By

ctDNA next generation sequencing of patient blood samples detected oncogenic drivers in 27 (36%) patients, including HER2 exon 20 insYVMA, BRAF L597Q, and MET exon14 mutations.

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

By

For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

By

Exon 20 mutations account for 4% to 10% of EGFR mutations in NSCLC and are refractory to EGFR TKIs; there are no targeted therapies available for this patient population.

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

By

During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC trial.

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

By

One-hundred and eight patients received cisplatin plus docetaxel in the control arm; 392 patients in the experimental arm received varying treatments according to BRCA1 mRNA expression levels.

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

By

For this cross-sectional study, researchers collected the data of 1030 adult patients with advanced NSCLC from medical chart reviews and various patient questionnaires.

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

By

Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin.

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

By

Researchers evaluated survival and socioeconomic data from 1,150,722 patients with NSCLC to determine particular factors that may predict OS.

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

By

Researchers administered savolitinib 600 mg plus gefitinib 250 mg to 44 patients, of whom 6 were T790M-positive and 5 were T790M-negative.

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

By

Investigators randomly assigned 95 patients with ED-SCLC to receive pazopanib 800 mg daily or placebo.

Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC

Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC

By

Researchers analyzed the resistance biopsies and plasma specimens of 119 patients with T790M-positive NSCLC treated with osimertinib.

Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC

By

Initial analysis of cohort G of KEYNOTE-021 at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate and progression-free survival compared with pemetrexed/carboplatin alone.

NSCLC: Bilateral Mediastinal Lymphadenectomy of Left Lobe Improves Survival

NSCLC: Bilateral Mediastinal Lymphadenectomy of Left Lobe Improves Survival

By

Researchers randomly assigned 89 patients with NSCLC to the SLND arm, in which patients underwent standard lung resection with SLND, or to the BML arm, in which patients received SLND plus contralateral mediastinal lymphadenectomy.

Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

By

Patients diagnosed with NSCLC between 2010 and 2013 had a median OS of 14.8 months compared with 12.4 months among patients diagnosed between 2004 and 2009.

Anetumab Ravtansine Does Not Improve PFS vs Vinorelbine in Second-line Mesothelioma

Anetumab Ravtansine Does Not Improve PFS vs Vinorelbine in Second-line Mesothelioma

By

Researchers enrolled 248 patients who progressed on pemetrexed-based chemotherapy with or without bevacizumab to receive second-line anetumab ravtansine or vinorelbine.

SABR Improves Overall Survival Compared With CRT in NSCLC

SABR Improves Overall Survival Compared With CRT in NSCLC

By

The purpose of this study was to compare the effectiveness of SABR with CRT in prolonging time to local failure in this patient population.

Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer

Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer

By

Researchers analyzed the outcomes of 7060 patients with SCLC from the SEER database to determine the rates of new CEs among patients treated with chemotherapy plus RT or chemotherapy alone.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs